Market research
SNG.LSE Synairgen plc
LSE GBP Healthcare
Latest close
As of 07 May 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- -2.23
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00B0381Z20
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- -2.23
About
About Synairgen plc
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Research context
Synairgen plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SNG.LSE discussion.
5 years, 6 months ago
Synairgen plc is currently in a long term uptrend where the price is trading 4.8% above its 200 day moving average.
From a valuation standpoint, the stock is 70.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 759.0.
Based on the above factors, Synairgen plc gets an overall score of 1/5.